Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | NUVB |
---|---|---|
09:32 ET | 34527 | 2.56 |
09:34 ET | 6393 | 2.61 |
09:36 ET | 2476 | 2.6 |
09:38 ET | 8448 | 2.62 |
09:39 ET | 200 | 2.62 |
09:41 ET | 7986 | 2.62 |
09:43 ET | 4980 | 2.625 |
09:45 ET | 29447 | 2.685 |
09:48 ET | 15588 | 2.695 |
09:50 ET | 3139 | 2.705 |
09:52 ET | 15510 | 2.71 |
09:54 ET | 2239 | 2.72 |
09:56 ET | 5820 | 2.715 |
09:57 ET | 5300 | 2.7397 |
09:59 ET | 16829 | 2.74 |
10:01 ET | 15260 | 2.765 |
10:03 ET | 13793 | 2.75 |
10:06 ET | 5590 | 2.755 |
10:08 ET | 2812 | 2.76 |
10:10 ET | 5847 | 2.745 |
10:12 ET | 6615 | 2.72 |
10:14 ET | 5800 | 2.7 |
10:15 ET | 14909 | 2.71 |
10:17 ET | 5598 | 2.72 |
10:19 ET | 2272 | 2.705 |
10:21 ET | 9988 | 2.7 |
10:24 ET | 3744 | 2.7 |
10:26 ET | 1827 | 2.685 |
10:28 ET | 7738 | 2.705 |
10:30 ET | 9882 | 2.73 |
10:32 ET | 3963 | 2.74 |
10:33 ET | 600 | 2.735 |
10:35 ET | 11757 | 2.715 |
10:37 ET | 14713 | 2.68 |
10:39 ET | 900 | 2.68 |
10:42 ET | 1991 | 2.665 |
10:44 ET | 13398 | 2.675 |
10:48 ET | 9554 | 2.66 |
10:50 ET | 100 | 2.6525 |
10:51 ET | 2024 | 2.66 |
10:53 ET | 1253 | 2.66 |
10:55 ET | 700 | 2.67 |
10:57 ET | 2331 | 2.675 |
11:00 ET | 700 | 2.68 |
11:02 ET | 6957 | 2.665 |
11:04 ET | 1559 | 2.66 |
11:06 ET | 300 | 2.65 |
11:08 ET | 800 | 2.655 |
11:09 ET | 2903 | 2.66 |
11:11 ET | 5978 | 2.64 |
11:13 ET | 881 | 2.65 |
11:15 ET | 2265 | 2.655 |
11:18 ET | 2224 | 2.64 |
11:22 ET | 2600 | 2.64 |
11:24 ET | 700 | 2.63 |
11:26 ET | 310 | 2.63 |
11:27 ET | 200 | 2.63 |
11:29 ET | 241 | 2.63 |
11:31 ET | 400 | 2.63 |
11:33 ET | 1200 | 2.63 |
11:36 ET | 973 | 2.635 |
11:38 ET | 700 | 2.635 |
11:40 ET | 10656 | 2.645 |
11:42 ET | 842 | 2.6499 |
11:44 ET | 2663 | 2.635 |
11:45 ET | 913 | 2.63 |
11:47 ET | 432 | 2.635 |
11:49 ET | 200 | 2.63 |
11:51 ET | 5497 | 2.645 |
11:54 ET | 400 | 2.64 |
11:56 ET | 1764 | 2.65 |
11:58 ET | 4175 | 2.635 |
12:00 ET | 3164 | 2.625 |
12:02 ET | 1600 | 2.62 |
12:03 ET | 2771 | 2.615 |
12:05 ET | 200 | 2.615 |
12:07 ET | 4162 | 2.605 |
12:09 ET | 200 | 2.6 |
12:12 ET | 10525 | 2.615 |
12:14 ET | 1221 | 2.615 |
12:16 ET | 3139 | 2.6 |
12:18 ET | 574 | 2.605 |
12:20 ET | 2825 | 2.59 |
12:21 ET | 100 | 2.59 |
12:23 ET | 1900 | 2.59 |
12:25 ET | 600 | 2.585 |
12:27 ET | 600 | 2.58 |
12:30 ET | 400 | 2.58 |
12:32 ET | 3589 | 2.595 |
12:34 ET | 4353 | 2.5999 |
12:36 ET | 557 | 2.595 |
12:38 ET | 1332 | 2.6 |
12:39 ET | 5252 | 2.595 |
12:41 ET | 300 | 2.595 |
12:43 ET | 4810 | 2.605 |
12:45 ET | 4557 | 2.595 |
12:48 ET | 100 | 2.59 |
12:52 ET | 6900 | 2.595 |
12:54 ET | 5500 | 2.6 |
12:56 ET | 2531 | 2.6 |
12:57 ET | 10729 | 2.61 |
12:59 ET | 4142 | 2.6 |
01:01 ET | 9974 | 2.605 |
01:03 ET | 1850 | 2.605 |
01:08 ET | 1400 | 2.605 |
01:10 ET | 4646 | 2.615 |
01:12 ET | 13806 | 2.63 |
01:14 ET | 3441 | 2.63 |
01:15 ET | 200 | 2.6375 |
01:17 ET | 400 | 2.64 |
01:19 ET | 5716 | 2.64 |
01:21 ET | 900 | 2.64 |
01:24 ET | 1000 | 2.635 |
01:26 ET | 3786 | 2.6488 |
01:28 ET | 2419 | 2.6475 |
01:30 ET | 3597 | 2.64 |
01:32 ET | 1150 | 2.64 |
01:33 ET | 4225 | 2.64 |
01:35 ET | 450 | 2.635 |
01:37 ET | 1215 | 2.64 |
01:39 ET | 5308 | 2.625 |
01:42 ET | 1000 | 2.63 |
01:44 ET | 900 | 2.63 |
01:46 ET | 400 | 2.63 |
01:48 ET | 700 | 2.63 |
01:50 ET | 600 | 2.625 |
01:51 ET | 2738 | 2.64 |
01:53 ET | 1100 | 2.64 |
01:55 ET | 1400 | 2.65 |
01:57 ET | 7157 | 2.635 |
02:00 ET | 630 | 2.635 |
02:02 ET | 4303 | 2.62 |
02:04 ET | 100 | 2.61 |
02:06 ET | 4639 | 2.605 |
02:08 ET | 1104 | 2.615 |
02:09 ET | 14270 | 2.6 |
02:11 ET | 770 | 2.6 |
02:13 ET | 1400 | 2.605 |
02:15 ET | 899 | 2.6 |
02:18 ET | 1900 | 2.605 |
02:20 ET | 3979 | 2.6 |
02:22 ET | 626 | 2.6 |
02:24 ET | 5791 | 2.59 |
02:26 ET | 4892 | 2.595 |
02:27 ET | 1491 | 2.59 |
02:29 ET | 900 | 2.59 |
02:31 ET | 14483 | 2.57 |
02:33 ET | 991 | 2.57 |
02:36 ET | 1789 | 2.57 |
02:38 ET | 589 | 2.57 |
02:40 ET | 954 | 2.575 |
02:42 ET | 8341 | 2.56 |
02:44 ET | 3164 | 2.565 |
02:45 ET | 720 | 2.565 |
02:47 ET | 1456 | 2.56 |
02:49 ET | 5064 | 2.56 |
02:51 ET | 51366 | 2.54 |
02:54 ET | 31226 | 2.545 |
02:56 ET | 600 | 2.54 |
02:58 ET | 300 | 2.54 |
03:00 ET | 2000 | 2.545 |
03:02 ET | 900 | 2.545 |
03:03 ET | 2895 | 2.54 |
03:05 ET | 3944 | 2.54 |
03:07 ET | 2700 | 2.54 |
03:09 ET | 3405 | 2.54 |
03:12 ET | 36213 | 2.54 |
03:14 ET | 14786 | 2.545 |
03:16 ET | 11400 | 2.54 |
03:18 ET | 2836 | 2.54 |
03:20 ET | 1855 | 2.54 |
03:21 ET | 94737 | 2.5421 |
03:23 ET | 1000 | 2.54 |
03:25 ET | 2090 | 2.54 |
03:27 ET | 4374 | 2.54 |
03:30 ET | 8070 | 2.54 |
03:32 ET | 1234 | 2.55 |
03:34 ET | 2804 | 2.54 |
03:36 ET | 3704 | 2.54 |
03:38 ET | 6648 | 2.54 |
03:39 ET | 43710 | 2.54 |
03:41 ET | 50610 | 2.52 |
03:43 ET | 76079 | 2.51 |
03:45 ET | 5003 | 2.51 |
03:48 ET | 3287 | 2.51 |
03:50 ET | 4177 | 2.51 |
03:52 ET | 13623 | 2.51 |
03:54 ET | 63256 | 2.515 |
03:56 ET | 68783 | 2.545 |
03:57 ET | 30105 | 2.565 |
03:59 ET | 40753 | 2.6 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Nuvation Bio Inc | 636.5M | -7.5x | --- |
Oric Pharmaceuticals Inc | 640.7M | -4.7x | --- |
Cogent Biosciences Inc | 632.0M | -2.8x | --- |
Mind Medicine (MindMed) Inc | 626.1M | -3.5x | --- |
Longboard Pharmaceuticals Inc | 648.9M | -7.3x | --- |
enGene Holdings Inc | 617.5M | -3.2x | --- |
Nuvation Bio Inc. is a biopharmaceutical company. The Company is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The Company is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. It is conducting Phase I/II study of NUV-1511.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $636.5M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 246.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.48 |
EPS | $-0.35 |
Book Value | $2.76 |
P/E Ratio | -7.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.